UNIGE document Scientific Article
previous document  unige:90077  next document
add to browser collection

Anticoagulation orale et pharmacogénétique : perspectives pour la pratique clinique

Published in Revue médicale suisse. 2007, vol. 3, no. 124, p. 2030-2036
Abstract Single nucleotide polymorphisms (SNPs) in genes encoding cytochrome P450 enzyme 2C9 (CYP2C9) and Vitamin K epoxide reductase subunit I (VKORC1) make a significant contribution to the inter-individual variability in the maintenance dose of vitamin K antagonists (warfarin, acenocoumarol, phenprocoumon). Doses requirements in CYP2C9*2 and CYP2C9*3 heterozygotes are reduced by 8-16% and 20-36%, respectively. SNP g-1639a in VKORC1 is also associated with vitamin K antagonists dosage since heterozygotes ga and homozygotes aa require respectively 21-28% and 27-56% less warfarin or acenocoumarol than homozygotes gg. CYP2C9 and VKORC1 account for up to half the variability in vitamin K antagonists requirements and incorporating genotying data for these two genes into dosing algorithms could lead to a safer anticoagulation therapy.
Keywords Anticoagulants/pharmacologyAryl Hydrocarbon Hydroxylases/geneticsCytochrome P-450 CYP2C9HumansMixed Function Oxygenases/geneticsPharmacogeneticsPolymorphism, Single NucleotideVitamin K/antagonists & inhibitorsVitamin K Epoxide Reductases
PMID: 17955831
Full text
This document has no fulltext available yet, but you can contact its author by using the form below.
Research group Groupe Desmeules Jules (pharmacologie/toxicologie) (567)
(ISO format)
BENUSIGLIO, Patrick Raphaël et al. Anticoagulation orale et pharmacogénétique : perspectives pour la pratique clinique. In: Revue médicale suisse, 2007, vol. 3, n° 124, p. 2030-2036. https://archive-ouverte.unige.ch/unige:90077

210 hits

0 download


Deposited on : 2016-12-08

Export document
Format :
Citation style :